Archive: October 2021

Evolving Strategies for the Management of Transformed Lymphoma

Sonali M. Smith, MD

H&O  What is transformed lymphoma? SS  Transformed lymphoma refers to a more aggressive or fast-growing lymphoma that arises from an indolent histology. The most common example […]

How Quality of Life Can Help Guide Selection of Androgen Receptor Inhibitors in Nonmetastatic Castration-Resistant Prostate Cancer

Matthew R. Smith, MD, PhD

H&O What are the treatment goals for men with nonmetastatic, castration-resistant prostate cancer (CRPC)? MS  Men with nonmetastatic, castration-resistant prostate cancer are at substantial risk for […]

Lessons Learned From the CAPTIVATE Trial of Ibrutinib Plus Venetoclax in CLL

Susan M. O’Brien, MD

H&O  Could you describe the design of the CAPTIVATE trial? SO  CAPTIVATE is a phase 2 trial in patients with previously untreated chronic lymphocytic leukemia (CLL) […]

Immunotherapy in Esophagogastric Cancer

David H. Ilson, MD, PhD

Abstract: The uses of immune checkpoint inhibitors have now been advanced to include the first-line treatment of esophagogastric cancers. Initially approved for the treatment of chemotherapy-refractory […]

Immunotherapy for Small Cell Lung Cancer: Established Applications and Novel Approaches

Susan C. Scott, MD, and Christine L. Hann, MD, PhD

Abstract: Small cell lung cancer (SCLC) is a devastating disease that has a case fatality rate of more than 90% despite best available treatments. As a […]

Neoadjuvant and Adjuvant Approaches in Surgically Resectable NSCLC

Jamie E. Chaft, MD

H&O  Which patients with non–small cell lung cancer (NSCLC) are eligible for surgical resection? JC  Surgical resectability, which is determined by the thoracic surgeon, is based […]

Letter From the Editor: Addressing the Racial Gap in Health Care

Daniel J. George, MD

I was disheartened when I read the article “The Black Mortality Gap, and a Document Written in 1910” in the August 30 edition of The New […]

Hem/Onc News

Devon Schuyler

Tisotumab Vedotin-tftv Approved for Recurrent or Metastatic Cervical Cancer On September 20, the US Food and Drug Administration (FDA) granted accelerated approval to tisotumab vedotin-tftv (Tivdak, […]

Back to Archive